25 May 2013
Keywords: mallinckrodt, optimark, completes, ph, ii, trials, usa-based
Article | 14 March 2005
USA-based Mallinckrodt, a business unit of Tyco Healthcare, has completed two Phase II studies using its OptiMARK imaging agent which
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com